Maia Biotechnology
MAIA · NYSE · United States
Share price · MAIA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MAIA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026+23.8%
- 30 Oct 2026-6.8%
Nothing announced by MAIA that day or the session before.
- 24 Sep 2026-5.3%
Nothing announced by MAIA that day or the session before.
- 18 Sep 2026-6.4%
Nothing announced by MAIA that day or the session before.
- 14 Sep 2026+6.9%
Nothing announced by MAIA that day or the session before.
- 16 Jul 2026-9.5%
Nothing announced by MAIA that day or the session before.
- 29 May 2026+7.8%
Nothing announced by MAIA that day or the session before.
- 3 Mar 2026-27.1%
Nothing announced by MAIA that day or the session before.
- 2 Feb 2026-19.5%
Nothing announced by MAIA that day or the session before.
- 29 Jan 2026-14.0%
Nothing announced by MAIA that day or the session before.
Share of unusual movement by asset
For each asset, the share of MAIA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Telomerase (hTERT)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | — | $0 | $7.2M-$6.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | — | $0 | $7.9M-$6.8M operating cash flow | report ↗ |
| 2026-Q1 | — | <$0.1M | — | $6.4M-$5.3M operating cash flow | report ↗ |
| 2025-Q3 | — | — | $0 | $8.9M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | — | — | $0 | $5.3M-$4.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $3.2M | $11M | $4.5M-$4.2M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.7M | $8.7M | $2.7M-$3.5M operating cash flow | report ↗ |
| 2024-Q2 | — | $2.0M | $12M | $8.9M-$4.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.3M | $8.3M | $8.1M-$3.6M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.6M | $6.1M | —-$3.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $2.6M | $9.2M | —-$2.6M operating cash flow | report ↗ |
| 2023-Q1 | — | $2.2M | $7.6M | —-$3.4M operating cash flow | report ↗ |
| 2022-Q3 | — | $2.3M | $14M | —-$4.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.1M | $8.2M | $3.3M-$2.0M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.1M | $10M | —-$2.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.1M | $11M | —-$1.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $0.5M | — | $5.6M-$19M operating cash flow | report ↗ |
For fiscal 2025, Maia Biotechnology did not disclose revenue (prior year $0M), reported R&D spend of $0.45M, down 95.5% YoY from $10.01M, and did not disclose cash and equivalents. The company reported a net loss of $22.4M and a quarterly net burn of $22.4M.
Insider transactions
Open-market activity, trailing 12 months: 34 purchases ($1.3M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Vitoc Vlad · director, Chief Executive Officer, 10% owner | Open-market purchase | 39,600 | $1.00 | $40K | Form 4 |
| 2026-11-16 | Smith Stan · director | Open-market purchase | 18,782 | $1.00 | $19K | Form 4 |
| 2026-11-13 | Vitoc Vlad · director, Chief Executive Officer, 10% owner | Open-market purchase | 60,400 | $1.00 | $60K | Form 4 |
| 2026-11-13 | Smith Stan · director | Open-market purchase | 81,218 | $1.00 | $81K | Form 4 |
| 2026-09-30 | CHAOUKI STEVEN M · director | Award / grant (derivative) | 32,774 | — | — | Form 4 |
| 2026-09-30 | Guerrero Ramiro · director | Award / grant (derivative) | 32,012 | — | — | Form 4 |
| 2026-09-30 | Louie Ngar Yee · director | Award / grant (derivative) | 39,634 | — | — | Form 4 |
| 2026-09-30 | Luput Cristian · director | Award / grant (derivative) | 33,536 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 13.1M shares ($18.3M, 21.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Solas Capital Management, LLC | 4,297,004 | $6.0M |
| 2 | Alyeska Investment Group, L.P. | 2,500,000 | $3.5M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,074,045 | $2.9M |
| 4 | 683 Capital Management, LLC | 1,066,666 | $1.5M |
| 5 | Centric Wealth Management | 796,723 | $1.1M |
| 6 | Cable Car Capital, LP | 648,503 | $908K |
| 7 | Bleichroeder LP | 500,000 | $700K |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 360,481 | $505K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 199,314 | $279K |
| 10 | STATE STREET CORP | 138,950 | $195K |
| 11 | BlackRock, Inc. | 127,978 | $179K |
| 12 | CORSAIR CAPITAL MANAGEMENT, L.P. | 100,000 | $140K |
| 13 | NORTHERN TRUST CORP | 52,539 | $74K |
| 14 | UBS Group AG | 51,917 | $73K |
| 15 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,000 | $50K |